Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity

被引:15
作者
Nakamura, Hiroshi [1 ]
Tamaki, Shigehiro [1 ]
Yagyuu, Takahiro [1 ]
Yamakawa, Nobuhiro [1 ]
Hatake, Katsuhiko [2 ]
Kirita, Tadaaki [1 ]
机构
[1] Nara Med Univ, Dept Oral & Maxillofacial Surg, 840 Shijo Cho, Kashihara, Nara 6348521, Japan
[2] Nara Med Univ, Dept Legal Med, Kashihara, Nara, Japan
关键词
Antibody-dependent cell-mediated cytotoxicity; cetuximab; EGFR natural killer cells; oral cancer; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CHIMERIC ANTIBODY; PLUS CETUXIMAB; PHASE-I; HEAD; THERAPY; COMBINATION; INHIBITION; CARCINOMA;
D O I
10.21873/anticanres.13238
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Cetuximab treatment targets the epidermal growth factor receptor (EGFR) overexpressed in oral cancer. This study aimed to investigate the antitumour activity of cetuximab against oral cancer cell lines with respect to antibody-dependent cell-mediated cytotoxicity (ADCC), and determine the correlation between ADCC and EGFR expression. Materials and Methods: EGFR expression in oral cancer cells was measured by quantitative flow cytometric analysis and immunohistochemistry. ADCC activity was measured by 4-h calcein release assays. Results: Cetuximab-mediated ADCC against oral cancer cells was detectable at a concentration of 0.1 mu g/ml. A high correlation was observed between the number of EGFR molecules on the surface of oral cancer cells and ADCC (correlation coefficient: 0.847; p=0.032). Conclusion: ADCC is an important mechanism underlying the therapeutic effect of cetuximab, and EGFR expression in tumour cells might serve as a predictive marker to evaluate the effect of cetuximab treatment.
引用
收藏
页码:1275 / 1282
页数:8
相关论文
共 33 条
[1]  
Ang KK, 2002, CANCER RES, V62, P7350
[2]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[3]   Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy [J].
Bleeker, WK ;
van Bueren, JJL ;
van Ojik, HH ;
Gerritsen, AF ;
Pluyter, M ;
Houtkamp, M ;
Halk, E ;
Goldstein, J ;
Schuurman, J ;
van Dijk, MA ;
van de Winkel, JGJ ;
Parren, PWHI .
JOURNAL OF IMMUNOLOGY, 2004, 173 (07) :4699-4707
[4]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[5]   Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck [J].
Bourhis, Jean ;
Rivera, Fernando ;
Mesia, Ricard ;
Awada, Ahmad ;
Geoffrois, Lionel ;
Borel, Christian ;
Humblet, Yves ;
Lopez-Pousa, Antonio ;
Hitt, Ricardo ;
Vega Villegas, M. Eugenia ;
Duck, Lionel ;
Rosine, Dominique ;
Amellal, Nadia ;
Schueler, Armin ;
Harstrick, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2866-2872
[6]  
FAN Z, 1993, CANCER RES, V53, P4322
[7]   IMAGING OF HUMAN-TUMOR XENOGRAFTS WITH AN INDIUM-111-LABELED ANTI-EPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY [J].
GOLDENBERG, A ;
MASUI, H ;
DIVGI, C ;
KAMRATH, H ;
PENTLOW, K ;
MENDELSOHN, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (21) :1616-1625
[8]  
Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
[9]   EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer [J].
Huether, A ;
Höpfner, M ;
Baradari, V ;
Schuppan, D ;
Scherübl, H .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (11) :1568-1578
[10]   Phase I Clinical Trial of Fibronectin CH296-Stimulated T Cell Therapy in Patients with Advanced Cancer [J].
Ishikawa, Takeshi ;
Kokura, Satoshi ;
Enoki, Tatsuji ;
Sakamoto, Naoyuki ;
Okayama, Tetsuya ;
Ideno, Mitsuko ;
Mineno, Junichi ;
Uno, Kazuko ;
Yoshida, Naohisa ;
Kamada, Kazuhiro ;
Katada, Kazuhiro ;
Uchiyama, Kazuhiko ;
Handa, Osamu ;
Takagi, Tomohisa ;
Konishi, Hideyuki ;
Yagi, Nobuaki ;
Naito, Yuji ;
Itoh, Yoshito ;
Yoshikawa, Toshikazu .
PLOS ONE, 2014, 9 (01)